​​ABOUT 11th_HTIF
> ATTENDEES
> INVESTORS
> PRESENTERS
> SUPPORTERS

20-minute presenters

Caresyntax Corp.

Caresyntax makes surgery safer, smarter and more profitable by converging medical-grade devices, AI-powered technology and clinical services. Founded in 2013, the company delivers a vendor-neutral platform solution which drives efficiencies throughout the peri-and intraoperative environment. For the first time, health care providers can access insights relating to clinical, financial, and operational outcomes from data collected in the operating room. Caresyntax is installed in 3,500 operating rooms across EMEA and US markets and supports over 3 million annual surgeries.​

caresyntax.com

Skymab Biotherapeutics

Skymab Biotherapeutics, a French biotech company spun out from the CEA (Commissariat à l'Énergie Atomique) in 2019, focuses on developing anti-GPCR Antibody Drug Conjugates (ADCs) to address critical unmet needs in oncology. Leveraging its proprietary target discovery algorithm and linker platform, Skymab's most advanced ADC candidate, now ready for IND-enabling studies, has been thoroughly validated in multiple animal proof-of-concept studies. This candidate presents significant opportunities for accelerated development in high unmet need indications, given its broad pan-tumor potential.​

www.skymab-biotherapeutics.com

Q3 Medical Devices Ltd.

At Q3 Medical Group, our vision of ""Creating Value by Helping People"" is the heartbeat of our mission. As a pioneering medical device company, we're transforming healthcare with our state-of-the-art innovations in biodegradable and micro-invasive technologies.

Specializing in surgical, gastrointestinal, and interventional treatments for both benign and malignant conditions of the Gastrointestinal and Vascular Systems, our groundbreaking innovations are crafted to elevate patient quality of life. By minimizing complications and eliminating the need for follow-up removal procedures, we’re not just improving patient outcomes—we’re also driving down costs and championing sustainability in the healthcare industry.

Q3 is a growth stage medical device implant company dedicated to developing groundbreaking, innovative products and bringing them to the global market.

www.q3medical.com

10-minute presenters

4D Lifetec AG

4D Lifetec offers an Artificial Intelligence (AI) backed immunological liquid biopsy platform that can be scaled offering multiple applications from Screening to Verification to Monitoring.

At 4D Lifetec, we recognize the boundless potential of AI in revolutionizing the early detection of cancer. With the power of AI, we are redefining the landscape of cancer diagnostics by opening up the horizon of our breakthrough innovation “4D Lifetest”, the first and only Immunological Liquid Biopsy Platform.

Human Peripheral Blood Mononuclear Cells (PBMCs), a group of white blood cells, react immediately as part of the immunological system to the presence of a cancerous tumor: its DNA fragmentation changes its behavior.

Our groundbreaking early cancer detection platform hinges on the combination of a proprietary high-precision method combined with the power of our own AI-based analysis tools. It allows us to detect multiple cancers independent from their stage.

A biomarker has no clinical use as long as the sensitivity is not above 75 - 80%. 4D Lifetest outperforms the most advanced genomic liquid biopsies regarding sensitivity for cancer stages I and II.
However, until now, 4D Lifetest Dx is not yet cancer type specific. Thanks to our investment and further development in our AI applications,  this will change within close future. AI combined with 4D Lifetest offers a unique scalability potential not only in volume but also types of applications addressing huge and fast growing market potentials. Our own AI enables 4D Lifetec to define cancer type and subtype detection which is key once the screening is applied.

4D Lifetec owns CE-IVD cerfiticates for its verification assays for breast, lung, prostate and bowel cancer and intents to commercialise its lung verification assay in the US beginning 2026 followed by an IPO at the US stock exchange.

www.4dlifetec.com

Brightmind.AI GmbH

Brightmind.AI is a pioneering neurotechnology company focused on improving brain health through personalized brain stimulation. Leveraging brain monitoring and transcranial magnetic stimulation, the company is developing effective, at-home treatments for neurological conditions such as migraines and dementia.
 
Mission:
To revolutionize brain health by making cutting-edge, non-invasive brain stimulation technology accessible for home use, thereby addressing critical challenges in neurological care.
 
First application: Migraine
Our first product addresses the literal pain point: migraine. Research indicates that our stimulation protocol reduces migraine attacks by over 6 days a month (placebo effect subtracted) offering a 3x improvement over current treatment options. This has been validated from both independent studies and Brightmind.AI's pilot study.
 
Technology:
Brightmind.AI uses a closed-loop system combining transcranial magnetic stimulation with advanced brain monitoring to synchronize and personalize brain stimulation.  
 
Partnerships and Funding:
The company is backed by Xista, with additional support from FFG and AWS and has raised 3.3M in capital.
 
Awards:
Brightmind.AI has received recognition and awards including the rising star award in the European start-up scene in MedTech from Sifted and the Innovator of the Year award in Austria.
 
Vision:
To integrate Brightmind.AI’s neurotech solutions into homes worldwide, improving quality of life and mental health on a global scale.

brightmind.ai

Hy2Care B.V.

Hy2Care revolutionizes cartilage repair with CartRevive® hydrogel implant of joint-matching composition, enabling the body to heal itself. It was founded by a patient, now in the clinical stage, ready to disrupt orthopedics.  
 
Hy2Care® is a ‘spin-off company’ of the Tech Med Centre at the University of Twente (NL) and was founded in 2014. Of the original founders, Prof. Dr. Marcel Karperien and Dr. Sanne Both, continue to be active in the company.  
Hy2Care’s launching product, the CartRevive® hydrogel implant for cartilage repair in the knee, is in the last phase of a clinical investigation in the Netherlands for European market approval. The first clinical results show significantly superior results compared to existing standard-of-care therapies. With the FDA Breakthrough Design Designation received, Hy2Care is currently preparing for IDE submission and intends to start initialization of its US trial in 2025.  
 
Hy2Care’s innovative platform centers on the CartRevive™ hydrogel implant's in-situ formation. Upon application to a cartilage defect, two naturally derived polymers, Dextran and Hyaluronic acid-conjugates, gelate within a minute. Simultaneously, the implant attaches itself to the surrounding cartilage and bone, providing a strongly fixated resorbable scaffold that degrades over time. The joint-mimicking composition forms a natural environment for the patient's cells to quickly populate the implant and initiate the natural repair of the cartilage.  
 
The unique therapy provides natural tissue healing, comparable to best-in-class cell-technology, at a fraction of the cost.  
 
Hy2Care is currently raising €9M series B round to complete preparations for the US trial, obtain CE mark and initiate first commercial treatments in Europe.  

www.hy2care.com

inHEART

inHEART advances precision medicine in cardiology with AI-based solutions for personalized treatment, prevention, and screening for cardiac diseases.​

www.inheartmedical.com

Lifespin GmbH

At lifespin we are pioneering precision health through the integration of AI-enhanced metabolomic measurements and digital twin technology. Lifespin’s cutting-edge platform merges advanced nuclear magnetic resonance (NMR), artificial intelligence, deep data analytics, and cloud technologies to establish a new frontier in personalized medicine. This revolutionary combination not only redefines existing benchmarks in oncology and other known medical conditions but also ventures into previously unexplored territories, such as specific neurological disorders.
 
Our proprietary AI transformer and foundation model are instrumental in deciphering the intricate relationships between clinical metabolomics and health conditions. By generating a novel metabolomic information layer, Lifespin’s platform facilitates transformative applications in preventive medicine, complex disease diagnostics, treatment monitoring, and patient stratification. The core of our innovation lies in our ability to capture and analyze individual metabolomes accurately, assessing hundreds of metabolite concentrations through a single NMR measurement.  
 
This presentation will highlight real-world applications from ongoing clinical studies in inflammatory, oncological, and neurological conditions, showcasing how our technology enables affordable, large-scale health screenings. With a self-evolving database encompassing over 250,000 human datasets—including healthy baselines and data from more than 700 disease phenotypes—Lifespin is at the vanguard of delivering personalized health solutions that significantly reduce healthcare costs and enhance accessibility on a global scale. Join us to explore how Lifespin is setting new standards in the healthcare industry, moving towards a future where healthcare is more proactive, personalized, and preventative.
 
Explainer Video: https://youtu.be/6wmTMXyXZ8M

lifespin.health

LuSeed Vascular

LuSeed Vascular is a pioneering medical technology startup that focuses on advancing neurovascular innovation for treating aneurysms in the brain.

Our primary commitment is to create and introduce groundbreaking devices that bring about significant improvements in the treatment outcomes of brain aneurysms.

The company’s flagship product, LuSeed’s DOME™, is a minimally invasive, is first of its class “one-and-done” device with the unique ability to treat both Bifurcation and Sidewall Brain aneurysms simply and safely, saving thousands of lives each year and disrupting the global market, valued more than 2.4B$.

The company’s leadership features extensive experience in the medical device domain and supported by top global KOLs in its field.

LuSeed has commenced its clinical phase, with so far highly promising results.

​luseed-vascular.com/

PamGene International B.V.

PamGene is a biomarker services company that has recently developed  the IOpener®  test. This is a CE-IVD certified product for the prediction of immunotherapy response for cancer patients in several indications (lung, skin, bladder, ovarium, prostate). The blood test is in the pivotal phase of commercialisation in Europe allowing for patient selection and guidance of immune therapy combination strategies in cancer care.

www.pamgene.com

rising healthtech stars SESSION

Alviv Laser Solutions

ALVIV is a bio-convergence medical device company developing a disruptive, short, pain-free laser-based treatment for Fecal Incontinence (FI). A condition that affects tens of millions of people around the world (1 of every 12 adults in the US). Currently, with no effective and consistent solutions especially for mild to moderate cases, holding immediate implications on patients' well-being and quality of life.

Harnessing tissue regeneration processes, ALVIV’s solution aims to introduce an innovative approach that serves as a breakthrough in FI management; by strengthening the internal sphincter in FI patients, we are addressing the source of the medical problem and not only the symptoms.

Our Vision:
We strive to become a leading player in FI illness management, with our laser-based treatment and patients standardized AI-based analysis. Scaling up, we will develop a home-use therapy for patients in-order-to provide access to a safe, effective, and easy-to-apply self-treatment option.

ALVIV’s team consists of leading experts bringing decades of experience and proven execution capabilities, developing energy-based medical solutions for various indications (from OBGYN, and proctology to autologous fat injection applications), validating them clinically and commercializing in global markets.

We are moving fast. With a fully functioning prototype and software, we are already in first-in-human safety and feasibility clinical study stage (Meir Medical Center, Israel).  Estimating to finalize patient recruitment within two months.

www.alvivlaser.com/

Gurmit Sandhu Consulting GmbH

Gurmit Sandhu Consulting GmbH has been registered with the Basel City commercial register since 2012.

With 35 years of experience, its founder and Managing Director, Gurmit Sandhu, is an experienced and respected specialist in the pharmaceuticals industry and digital health.

Value Assessment of Digital Health Technologies for improving their market access, reimbursability, and adoption has been a focus since 2019.

www.linkedin.com/in/gurmitsandhu

Oncosema

Founded in June 2022, Oncosema is a French IVD upstart dedicated to developing, manufacturing and commercializing innovative tests for the detection and quantification of Circulating Tumor Cells in blood as a biomarker of cancer progression.​

www.oncosema.com

Panda Surgical

Panda Surgical, a University College London spinout, is developing the first-ever handheld robotics platform for minimally invasive neurosurgery, offering surgeons enhanced dexterity and decision-support to make these operations safer, more effective, and more widely adopted. 

www.panda-surgical.com

Rosetta Omics

Rosetta Omics is a French healthcare deeptech startup in a mission is to revolutionize precision medicine, starting with cancer, by integrating multiomics data from patient tumors, clinical records, and advanced machine learning/AI algorithms.

Our innovative approach aims to enhance the prediction of treatment responses, providing physicians with critical insights to prescribe the most effective therapies for their patients at the right time to save lives and cost. At the moment, response rate at first line is very low and physicians need tools like ours to help them. 

Additionally, we are collaborating with pharmaceutical companies to discover new biomarkers and targets, aiding in drug discovery and patient stratification during clinical trials to accelerate the development of safe and effective cancer treatments. We have already initiated discussions with several leading pharmaceutical firms.

rosettaomics.fr/

Swiift Imaging SAS

Swiift Imaging - Quality ultrasound, anytime, anywhere.

Ultrasound is the second most used imaging modality (5x more than CT scan) and the only one not to be used in routine tele-imaging.

Faced with the significant difficulties in patient access to ultrasound, particularly outside metropolitan areas, Swiift Imaging offers the first long-distance remote robotic ultrasound solution with force feedback allowing the radiologist to apply their know-how as at the patient's bedside. To this end, the company has invested in a strong R&D program, thus ensuring a solid IP.

Swiift Imaging's solution is the missing link in the pooling of medical imaging resources.

Swiift Imaging offers a remote robotic ultrasound solution made of two interdependent medical devices: - One side for radiologists including ultrasound data transfer and a haptic arm enabling the exam as at the patient's bedside - One for institutions requiring ultrasound scans for their patients with a robotic arm holding the ultrasound probe.

swiiftimaging.com/

VUS Diagnostics

VUS Diagnostics is a genetic focused precision diagnostic company on a mission to help bring personalised treatment approaches to patients. We do this by designing CRISPR based functional assays that address the mechanism underlying the disease biology or drug response. Using such functional assays, we help drug developers identify the patients for whom their precision medicine can reverse disease pathology, or provide more specific cancer treatments.

www.vusdx.com/

virtual showcases

Brenus Pharma

Brenus Pharma is a French clinical-stage biotech developing a pioneering technology platform, Stimulated-Tumor-Cell (STC) designed to generate 'first-in-class', 'off-the-shelf' therapeutic cancer vaccine leading the way to a new precision medicine in immuno-oncology.  

Brenus Pharma is on the brink of a breakthrough and will start its first-in-human study in 2024 in colorectal cancer (mCRC), 2nd cause of cancer-related deaths wordlwide. 

We are building a strong portfolio in solid tumors, leveraging our patented STC platform, to change a paradigm in oncology.

www.brenus-pharma.com

NovaPump GmbH

The NovaPump GmbH develops highly innovative solutions for catheter-based circulation support, produced it in clean environment and brings them to market. The interdisciplinary team of experienced experts in cardiology, medical technology and international product approval is dedicated to saving lives through novel solutions in the field of interventional cardiology. The PERKAT RV is a catheter-based, percutaneously implantable short-term heart pump. It is driven by the proven IABP technology in a pulsatile manner. The main component is a self-expanding nitinol pump chamber, combined with an innovative, patented foil valve system. The entire pump is folded into an 18F catheter and can be minimally invasively implanted in acute emergency situations (off-pump while beating heart) due to its compact size within less than 5 min under X-Ray control.

NovaPump - Innovation at Heart

www.novapump.de